Moody Aldrich Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Moody Aldrich Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,049	Closed	-$616K	–	202
2024 Q1	$616K	Hold	7,049	–	–	0.1%	132
2023 Q4	$680K	Buy	7,049 +1,392	+25%	+$123K	0.12%	123
2023 Q3	$501K	Buy	+5,657	New	+$503K	0.09%	128

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Moody Aldrich Partners's BMRN Position: Q2 2024 in Review

Moody Aldrich Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 7,049 shares — an estimated $616K sold.

Moody Aldrich Partners first reported a position in BMRN in Q3 2023 and held it in 3 quarters. The position peaked at $680K in Q4 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Moody Aldrich Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Moody Aldrich Partners sold 7,049 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $616K.
Moody Aldrich Partners first reported a position in BioMarin Pharmaceuticals in Q3 2023 and held it in 3 quarters.
Moody Aldrich Partners's BioMarin Pharmaceuticals position peaked at $680K in Q4 2023.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Moody Aldrich Partners's 13F filing for Q2 2024, filed 24 Jul 2024.